Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)

Study design is followings: The sample size was calculated according to Simon's two stage optimal design. Assuming a response rate of 40%, a probability of error of 5% and a power of 80%, a total of 48 patients (43 patients plus 5 patients to compensate a 10% drop-out rate) were enrolled. In the initial stage, 13 evaluable patients were to be entered into the study and evaluated for their response. If ≥ 3 responses were observed during the first stage, then 30 additional patients were to be entered in the second stage. The statistical evaluation was performed based on the intention to-treat analysis.

The combination chemotherapy consisted of docetaxel of 40mg/m2 as a 1-hour infusion followed by cisplatin 40mg/m2 as a 30-minutes intravenous infusion and both drugs were given on days 1, and 15 in an outpatient setting. Patients also received adequate hydration with at least 1,500ml of half saline or normal saline before cisplatin administration. All the patients received antiemetic therapy that consisted of intravenous 5-HT3 antagonist and dexamethasone before docetaxel administration. The treatment cycles were repeated every 4 weeks until the maximum six cycles.

The patients whose absolute neutrophil count and platelet count were greater than or equal to 1.500 and 100,000/mm3, respectively, and who had lower than or equal to grade 1 non-hematologic toxicity (excluding alopecia) received chemotherapy on day 1 of each cycle.

On days 15 of each cycle, the minimum requirements to receive chemotherapy were an absolute neutrophil count between 1000 and 1,500/mm3, a platelet count ≥75,000/mm3 and no grade ≥2 nonhematologic toxicity (excluding alopecia).

If these conditions were not met on days 1, or 15, then chemotherapy was postponed for 1 week. A delay of more than 3 weeks resulted in withdrawal from the study.

If there were any grade 3 to 4 hematologic toxicities at the nadir of the previous cycle, or febrile neutropenia with or without documented infection, then administration of both drugs in the subsequent cycles was reduced by 25% from the planned dose.

The Administration of granulocyte-colony stimulating factor (G-CSF) was allowed in the presence of febrile neutropenia, and grade 3 or 4 neutropenia.

In the presence of grade 3 or 4 non-hematologic toxicity (except nausea, vomiting and alopecia), the treatment was postponed until resolution of the toxicity and then both drug doses were reduced by 25% for the next cycle. Treatment was stopped at any time for documented disease progression, unacceptable toxicity or according to the patient's own refusal.

The pretreatment baseline evaluation included a complete medical history and physical examination, a complete blood cell count (CBC) with the differentials, chemistry profiles and performance status. Chest X-rays, chest and upper abdominal computed tomography (CT) scans, brain CT scan or magnetic resonance imaging, a radionuclide bone scan and other diagnostic procedures were performed as clinically indicated.

During treatment, a limited history taking, physical examination, assessment of toxicity, a complete blood cell count with the differentials and blood chemistry tests were repeated weekly. A chest X-ray was performed every 4 weeks before each cycle.

Appropriate imaging studies, including CT scans of the chest and upper abdomen, were performed every two cycles to assess the treatment response, and sooner if needed for documenting disease progression. The objective tumor responses were assessed according to the RECIST criteria. The response rate was calculated as the ratio of the number of patients who achieved a complete or partial response to the number of enrolled patients. Overall survival (OS) and Time to progression (TTP) were calculated from the start of therapy until death and progression, respectively, or until the last follow-up. Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale version 3.0.

Inclusion criteria

• patients who were≥ 65 years of age and they had an Easten Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, or the patients who were < 65 years of age and they had an ECOG PS 2
• histologically confirmed non-small cell carcinoma
• stages IIIB-IV disease
• adequate hematologic parameters (hemoglobin concentration of at least 9.0 g/dL, absolute neutrophil count ≥1,500/mm3, and platelet count ≥100,000/mm3), renal function (serum creatinine ≤1.5 mg/dL), and liver function (total bilirubin ≤1.5 mg/dL and serum transaminase level less than twice the upper limit of normal)
• at least one bi-dimensionally measurable lesion, according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1

Exclusion criteria

• Active infection
• Prior chemotherapy, radiotherapy or surgery for their disease,
• A history of myocardial infarction in the last 3 months before entry to the study
• Uncontrolled congestive heart failure or hypertension
• Uncontrolled diabetes mellitus, pregnancy, lactation or a prior second primary cancer except for cervix cancer in situ or skin cancer
• All the patients provided written informed consent before they entered the study